Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Garcia, 2007 Kamangar, 2006, Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world, J Clin Oncol, 24, 2137, 10.1200/JCO.2005.05.2308 Cunningham, 2006, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, N Engl J Med, 355, 11, 10.1056/NEJMoa055531 Horner Cunningham, 2005, Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution, J Gastrointest Surg, 9, 718, 10.1016/j.gassur.2004.12.002 Wagner, 2006, Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data, J Clin Oncol, 24, 2903, 10.1200/JCO.2005.05.0245 Cunningham, 2008, Capecitabine and oxaliplatin for advanced esophagogastric cancer, N Engl J Med, 358, 36, 10.1056/NEJMoa073149 Kang, 2009, Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial, Ann Oncol, 20, 666, 10.1093/annonc/mdn717 Gravalos, 2008, HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target, Ann Oncol, 19, 1523, 10.1093/annonc/mdn169 Hofmann, 2008, Assessment of a HER2 scoring system for gastric cancer: results from a validation study, Histopathology, 52, 797, 10.1111/j.1365-2559.2008.03028.x Tanner, 2005, Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab, Ann Oncol, 16, 273, 10.1093/annonc/mdi064 Hudis, 2007, Trastuzumab—mechanism of action and use in clinical practice, N Engl J Med, 357, 39, 10.1056/NEJMra043186 Piccart-Gebhart, 2005, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med, 353, 1659, 10.1056/NEJMoa052306 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101 Smith, 2007, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial, Lancet, 369, 29, 10.1016/S0140-6736(07)60028-2 Dowsett, 2009, Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial, J Clin Oncol, 27, 2962, 10.1200/JCO.2008.19.7939 Fujimoto-Ouchi, 2007, Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models, Cancer Chemother Pharmacol, 59, 795, 10.1007/s00280-006-0337-z Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707, 10.1126/science.2470152 Dybdal, 2005, Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab, Breast Cancer Res Treat, 93, 3, 10.1007/s10549-004-6275-8 Penault-Llorca F, Vincent-Salomon A, Mathieu MC, Trillet-Lenoir V, Khayat D, Marty M, on behalf of the Esther Study Group. Incidence and implications of HER2 and hormonal receptor overexpression in newly diagnosed metastatic breast cancer (MBC). ASCO Annual Meeting; Orlando, FL, USA; May 13–17, 2005. Glimelius, 1997, Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer, Ann Oncol, 8, 163, 10.1023/A:1008243606668 Pyrhonen, 1995, Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer, Br J Cancer, 71, 587, 10.1038/bjc.1995.114 Ohtsu, 2003, Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205), J Clin Oncol, 21, 54, 10.1200/JCO.2003.04.130 Van Cutsem, 2006, Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group, J Clin Oncol, 24, 4991, 10.1200/JCO.2006.06.8429 Al Batran, 2008, Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie, J Clin Oncol, 26, 1435, 10.1200/JCO.2007.13.9378 Okines, 2009, Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer, Ann Oncol, 20, 1529, 10.1093/annonc/mdp047 Wagner, 2010, Chemotherapy for advanced gastric cancer, Cochrane Database Syst Rev, 3, 10.1002/14651858.CD004064.pub3 Yamashita, 2009, Diffuse type advanced gastric cancer showing dismal prognosis is characterized by deeper invasion and emerging peritoneal cancer cell: the latest comparative study to intestinal advanced gastric cancer, Hepatogastroenterology, 56, 276 Miyahara, 2007, Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population: data from a single institute over 30 years, J Gastroenterol Hepatol, 22, 1435, 10.1111/j.1440-1746.2007.04991.x Zheng, 2007, Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray, J Clin Pathol, 60, 273, 10.1136/jcp.2006.038778 Vogel, 2002, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer, J Clin Oncol, 20, 719, 10.1200/JCO.20.3.719 Yoshida, 2009, Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity, J Mol Cell Cardiol, 47, 698, 10.1016/j.yjmcc.2009.07.024